Theravance Biopharma (NASDAQ:TBPH) Upgraded at Zacks Research

Zacks Research upgraded shares of Theravance Biopharma (NASDAQ:TBPH) from a hold rating to a strong-buy rating in a report released on Thursday morning,Zacks.com reports.

A number of other analysts have also recently issued reports on TBPH. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research note on Thursday, January 22nd. B. Riley Financial reissued a “neutral” rating and issued a $14.00 price target (down from $28.00) on shares of Theravance Biopharma in a report on Wednesday, March 4th. Wall Street Zen downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday. Oppenheimer cut Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $21.00 target price on shares of Theravance Biopharma in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $22.60.

Theravance Biopharma Price Performance

Theravance Biopharma stock opened at $14.33 on Thursday. The company has a market capitalization of $726.10 million, a PE ratio of 7.06 and a beta of 0.17. The business has a 50 day simple moving average of $18.00 and a 200 day simple moving average of $16.87. Theravance Biopharma has a one year low of $7.90 and a one year high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Wednesday, March 25th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.71. The company had revenue of $45.89 million for the quarter, compared to analyst estimates of $43.09 million. Theravance Biopharma had a net margin of 98.54% and a return on equity of 18.55%. Equities analysts anticipate that Theravance Biopharma will post -1.09 earnings per share for the current fiscal year.

Insider Activity

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the transaction, the senior vice president owned 232,699 shares in the company, valued at $3,248,478.04. This trade represents a 11.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

A number of large investors have recently bought and sold shares of TBPH. Arrowstreet Capital Limited Partnership bought a new position in shares of Theravance Biopharma in the third quarter worth about $10,611,000. Assenagon Asset Management S.A. increased its stake in shares of Theravance Biopharma by 1,629.4% in the third quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock valued at $6,055,000 after buying an additional 390,735 shares during the period. Pacer Advisors Inc. acquired a new position in shares of Theravance Biopharma in the fourth quarter worth approximately $6,342,000. Hillsdale Investment Management Inc. bought a new position in Theravance Biopharma during the 3rd quarter worth approximately $4,536,000. Finally, Janus Henderson Group PLC boosted its stake in shares of Theravance Biopharma by 214.8% in the 4th quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock valued at $7,493,000 after purchasing an additional 273,288 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

More Theravance Biopharma News

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Company highlights and cash/milestone strength — Theravance reported record brand-level profitability for YUPELRI®, received milestone payments tied to sales, expects ~ $400M in cash at end-Q1 2026 with no debt, and announced cost-reduction targets to generate $60–$70M of annualized cash flow starting Q3 2026. Theravance Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Analyst optimism — BTIG reaffirmed a buy rating and set a $21 price target (material upside from current levels), and Zacks upgraded TBPH to a Rank #1 (Strong Buy), supporting the short-term positive sentiment. Benzinga Zacks: Rating Upgrade to Strong Buy
• Neutral Sentiment: Mixed earnings coverage — company releases show strong non‑GAAP profitability and reported milestone-driven revenue, but media/analytics outlets are publishing differing EPS figures (reports vary between a beat and a miss depending on metric/adjustment). Investors should check the company filing for GAAP vs. non‑GAAP reconciliations. Press Release — Q4 and Full Year 2025 Results Zacks: Q4 Earnings and Revenues Lag Estimates
• Negative Sentiment: Pipeline setback and strategic review — management discontinued ampreloxetine after Phase 3 CYPRESS results, is implementing a restructuring, and has formed a Strategic Review Committee to evaluate options including a potential sale — these actions reduce near-term R&D upside and signal material change in corporate strategy. Zacks: Q4 Earnings and Revenues Miss; Ampreloxetine Scrapped
• Negative Sentiment: Insider selling — SVP Rhonda Farnum sold ~31,067 shares in mid‑March; while not definitive, the sale is being watched by investors as a near-term negative signal. InsiderTrades: SVP Sells Shares

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.